{
    "clinical_study": {
        "@rank": "107581", 
        "arm_group": [
            {
                "arm_group_label": "SOTB07 200mg", 
                "arm_group_type": "Experimental", 
                "description": "SOTB07 200mg"
            }, 
            {
                "arm_group_label": "SOTB07 400mg", 
                "arm_group_type": "Experimental", 
                "description": "SOTB07 400mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the efficacy and safety of SOTB07 in asthma\n      patients by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral\n      administration of SOTB07 200mg, 400mg, placebo for 12 weeks."
        }, 
        "brief_title": "Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients", 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "A 12-week, Multi-center, Randomized, Double blinded, Parallel group, Placebo-controlled\n      study to Assess the Efficacy and Safety of SOTB07 in asthma patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or eligible female subjects aged 15 years or more\n\n          2. A female is eligible if she is of:\n\n               -  Non-child bearing potential (i.e., physiologically incapable of becoming\n                  pregnant), including any female who is at least 2 year after post- menopausal\n\n               -  Child bearing potential and agrees to the acceptable contraceptive methods used\n                  consistently and correctly\n\n               -  Negative pregnancy test at screening\n\n          3. Non-smoker for at least 1 year, a pack history of \u2264 10 pack years\n\n          4. Symptom of persistent asthma, as defined by the National Institute of Health (NIH)\n             5.50% \u2264 FEV1 \u2264 80% predicted at screening visit (withholding inhaled, short acting\n             \u00df-agonist for 6 hours)\n\n        6.FEV1 reversibility \u2265 12% and 200 ml at 20-30 minutes after inhalation of a short acting\n        \u00df-agonist (Salbutamol 2 puffs; 200\u338d) at Visit 1 or within 6 months before Visit 1\n        7.Capable of withholding salbutamol use for \u2265 6 hours prior to clinic visits\n        8.Appropriately signed and dated informed consent has been obtained\n\n        Exclusion Criteria:\n\n          1. Active upper or lower respiratory tract infection within 3 weeks before visit 1\n\n          2. Emergency room treatment for asthma within 1 month or hospitalization for asthma\n             within 3 months before visit 1\n\n          3. Any evidence of infectious, oncologic, or other active pulmonary disease obtained by\n             chest radiography within 12 months before visit 1\n\n          4. Clinically significant, in the opinion of the investigator, hematological, liver,\n             renal, heart, neurological disease, or other serious disease\n\n          5. Hypersensitivity to any \u03b22-agonist, sympathomimetic drug, leukotriene receptor\n             antagonist or Sophora tonkinensis Radix Rhizoma\n\n          6. Clinically significant and uncontrolled psychiatric disease\n\n          7. history of drug or alcohol abuse\n\n          8. Inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1\n\n          9. Change of Immunotherapy within 6 months before visit 1\n\n         10. Administration of the antiasthma agent within 1 week of visit 1\n\n         11. Administration of any other medication which may affect the course of asthma, or\n             interact with sympathomimetic amines\n\n         12. Participation in study using an experimental medication within 1 month before visit 1\n\n         13. Other ineligible subject in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "276", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907763", 
            "org_study_id": "SOTB07_AST_III_2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "SOTB07 200mg", 
                "intervention_name": "SOTB07 200mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SOTB07 400mg", 
                "intervention_name": "SOTB07 400mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "asthma", 
            "SOTB07"
        ], 
        "lastchanged_date": "July 22, 2013", 
        "location": {
            "contact": {
                "email": "shcho@plazasnu.ac.kr", 
                "last_name": "Sangheon Cho, professor", 
                "phone": "82-2-2112-5610"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 12-week, Multi-center, Randomized, Double Blinded, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients", 
        "overall_contact": {
            "email": "guinea71@snu.ac.kr", 
            "last_name": "Sangheon Cho, professor", 
            "phone": "82-2-2072-0699"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "FEV1 change from the baseline", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907763"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in spirometer parameters", 
                "safety_issue": "No", 
                "time_frame": "12  weeks"
            }, 
            {
                "measure": "Change in FeNO", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in AM/PM PEFR", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in diurnal asthma symptom score", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in the number of days with experience of nocturnal asthma symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in amount of beta-2 agonist used (puff/day)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of rescue free day", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of asthma control day", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of asthma exacerbation", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Proportion of treatment failure (severe asthma exacerbation)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes in asthma control questionaire score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes in quality of life questionaire for adult korea asthmatics scores", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Changes in patient's global self assessment score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in visual analogue scale for cough score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in biomarkers (eosinophil, neutrophil, ECP, eotaxin) in blood sample", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in biomarkers (eosinophil, neutrophil, ECP, eotaxin) in sputum sample", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "SK Chemicals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SK Chemicals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}